Want to see ES:PRM full AI Analyst Report?
Top Page
PRIM, S.A.
(BME:PRM)
Select Model
Select Model
Rating:76Outperform
Price Target:
€15.00
▲(12.36% Upside)
Action:Reiterated
Date:08/04/26
Overall score is driven primarily by strong financial positioning—especially the debt-free balance sheet and improving profitability—offset by uneven cash-flow consistency and a 2025 free-cash-flow step-down. Technicals are supportive with price above key moving averages, though near-term momentum looks stretched (very high stochastic). Valuation is a positive contributor with a moderate P/E and a solid dividend yield.
Positive Factors
Debt-free balance sheet
Being effectively unlevered provides durable financial flexibility: lower interest burden, more optionality for capex, dividends or bolt-on M&A, and greater resilience to cyclical shocks. Over the next 2–6 months this supports stable operations and strategic optionality.
Negative Factors
Uneven cash generation
Intermittent negative operating and free cash flow in prior years plus a 2025 FCF step-down versus 2024 signal that cash conversion is inconsistent. This reduces the reliability of internally funded growth and increases sensitivity to working-capital swings and capex over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
Being effectively unlevered provides durable financial flexibility: lower interest burden, more optionality for capex, dividends or bolt-on M&A, and greater resilience to cyclical shocks. Over the next 2–6 months this supports stable operations and strategic optionality.
Read all positive factors
PRIM, S.A. (PRM) vs. iShares MSCI Spain ETF (EWP)
Market Cap
€226.27M
Dividend Yield3.39%
Average Volume (3M)3.97K
Price to Earnings (P/E)13.6
Beta (1Y)0.26
Revenue Growth4.20%
EPS Growth-10.44%
CountryES
Employees959
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)0.98
Shares Outstanding17,036,577
10 Day Avg. Volume4,234
30 Day Avg. Volume3,973
Financial Highlights & Ratios
PEG Ratio0.25
Price to Book (P/B)163.15
Price to Sales (P/S)89.18
P/FCF Ratio1.24K
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.16
Revenue Forecast (FY)€270.70M
PRIM, S.A. Business Overview & Revenue Model
Company Description
Prim, S.A., operating through its various affiliated entities, specializes in the conception, production, and sale of orthopedic solutions. These items are utilized across diverse fields such as physical therapy, aquatic therapies (like thalassoth...
How the Company Makes Money
PRIM, S.A. makes money primarily by selling healthcare and medical-technology products to professional and institutional customers (e.g., hospitals, clinics, pharmacies, orthopedic and rehabilitation centers) as well as through retail channels whe...
PRIM, S.A. Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
90
Very Positive
Cash Flow
62
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 251.82M | 233.15M | 216.51M | 197.25M | 168.51M |
| Gross Profit | 127.01M | 112.62M | 45.30M | 94.56M | 83.08M |
| EBITDA | 33.94M | 26.23M | 28.05M | 19.71M | 30.18M |
| Net Income | 16.68M | 10.92M | 12.67M | 8.39M | 17.42M |
Balance Sheet | |||||
| Total Assets | 196.53M | 190.28M | 200.10M | 184.99M | 179.85M |
| Cash, Cash Equivalents and Short-Term Investments | 23.03M | 13.75M | 13.25M | 14.94M | 36.54M |
| Total Debt | 16.28M | 18.50M | 25.48M | 22.07M | 19.07M |
| Total Liabilities | 58.89M | 61.34M | 74.28M | 65.28M | 58.38M |
| Stockholders Equity | 137.64M | 128.93M | 125.82M | 119.71M | 121.47M |
Cash Flow | |||||
| Free Cash Flow | 18.14M | 10.76M | -20.09M | -7.02M | 13.87M |
| Operating Cash Flow | 30.46M | 22.11M | -11.33M | 4.89M | 26.30M |
| Investing Cash Flow | -10.07M | -7.59M | -3.67M | -14.10M | -8.70M |
| Financing Cash Flow | -11.62M | -11.32M | 10.46M | -12.19M | -15.09M |
PRIM, S.A. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | €226.27M | 13.62 | 12.34% | 3.39% | 4.20% | -10.44% | |
69 Neutral | €1.49B | 25.73 | 23.64% | 1.25% | 15.52% | 34.76% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | €236.53M | -92.50 | -2.03% | ― | ― | 53.50% | |
43 Neutral | €195.26M | -1.94 | -51.00% | ― | -33.72% | -215.75% |
* Healthcare Sector Average
ES:PRM
PRIM, S.A.
13.35
1.73
14.92%
ES:ORY
Oryzon Genomics SA
2.89
0.23
8.50%
ES:PHM
Pharma Mar SA
83.95
0.37
0.44%
ES:ATRY
Atrys Health SA
2.57
-0.37
-12.59%
ES:LAB
Labiana Health SA
6.55
2.70
70.35%
ES:STNA
Santa Ana Global Enterprises SA
15.40
1.80
13.24%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.